Jaguar Health, Inc.Find Ratings Reports
JAGUAR HEALTH INC's gross profit margin for the fourth quarter of its fiscal year 2020 has increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. JAGUAR HEALTH INC has weak liquidity. Currently, the Quick Ratio is 0.96 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 16.36% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY20||Q4 FY19|
|Net Sales ($mil)||2.58||1.51|
|Net Income ($mil)||-8.77||-5.96|
|Balance Sheet||Q4 FY20||Q4 FY19|
|Cash & Equiv. ($mil)||8.09||3.88|
|Total Assets ($mil)||42.84||36.41|
|Total Debt ($mil)||16.21||7.57|
|Profitability||Q4 FY20||Q4 FY19|
|Gross Profit Margin||86.1||73.86|
|Return on Assets||-78.91||-105.84|
|Return on Equity||-219.7||-217.45|
|Debt||Q4 FY20||Q4 FY19|
|Share Data||Q4 FY20||Q4 FY19|
|Shares outstanding (mil)||116.14||54.57|
|Div / share||0.0||0.0|
|Book value / share||0.15||0.38|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1.2473418E7||6.1216736E7|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 10.26 indicates a significant premium versus the S&P 500 average of 4.43 and a significant premium versus the subsector average of 6.69. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. Upon assessment of these and other key valuation criteria, JAGUAR HEALTH INC seems to be trading at a premium to investment alternatives.
|JAGX NM||Peers 29.68||JAGX NM||Peers 18.29|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
JAGX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
JAGX's P/CF is negative making the measure meaningless.
|JAGX NM||Peers 17.42||JAGX NA||Peers 0.45|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
JAGX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|JAGX 10.26||Peers 6.69||JAGX 96.07||Peers -25.59|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
JAGX is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
JAGX is expected to have an earnings growth rate that significantly exceeds its peers.
|JAGX 18.80||Peers 11.70||JAGX 62.51||Peers 53.69|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
JAGX is trading at a significant premium to its subsector.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
JAGX has a sales growth rate that exceeds its peers.